- Home
- MAC vs RNA Comparison
MAC vs RNA Comparison
Compare MAC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- RNA
- Stock Information
- Founded
- MAC 1964
- RNA 2012
- Country
- MAC United States
- RNA United States
- Employees
- MAC N/A
- RNA N/A
- Industry
- MAC Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- MAC Real Estate
- RNA Health Care
- Exchange
- MAC Nasdaq
- RNA Nasdaq
- Market Cap
- MAC 4.3B
- RNA 4.0B
- IPO Year
- MAC 1994
- RNA 2020
- Fundamental
- Price
- MAC $17.17
- RNA $70.78
- Analyst Decision
- MAC Hold
- RNA Buy
- Analyst Count
- MAC 11
- RNA 20
- Target Price
- MAC $19.67
- RNA $69.26
- AVG Volume (30 Days)
- MAC 1.7M
- RNA 10.2M
- Earning Date
- MAC 11-04-2025
- RNA 11-10-2025
- Dividend Yield
- MAC 3.96%
- RNA N/A
- EPS Growth
- MAC N/A
- RNA N/A
- EPS
- MAC N/A
- RNA N/A
- Revenue
- MAC $1,099,978,000.00
- RNA $20,868,000.00
- Revenue This Year
- MAC $12.20
- RNA N/A
- Revenue Next Year
- MAC $0.20
- RNA $108.97
- P/E Ratio
- MAC N/A
- RNA N/A
- Revenue Growth
- MAC 39.55
- RNA 106.27
- 52 Week Low
- MAC $12.48
- RNA $21.51
- 52 Week High
- MAC $22.27
- RNA $71.09
- Technical
- Relative Strength Index (RSI)
- MAC 44.82
- RNA 80.52
- Support Level
- MAC $17.30
- RNA $69.67
- Resistance Level
- MAC $18.30
- RNA $70.98
- Average True Range (ATR)
- MAC 0.55
- RNA 0.28
- MACD
- MAC -0.03
- RNA -0.21
- Stochastic Oscillator
- MAC 33.73
- RNA 84.28
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.2 million square feet of gross leasable area and averaged $849 sales per square foot over the 12 months ended in June 2025.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.